COVID-19 treatment sotrovimab could be helpful for high-risk patients

Embargoed until: Publicly released: 2021-10-28 08:00

International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

Sotrovimab could be a helpful COVID-19 treatment for high-risk patients, according to international researchers who saw reduced disease progression when given early on in the course of the disease. Of the 291 patients treated with sotrovimab, only three patients (1 per cent) had disease progression leading to hospitalisation or death, compared to 21 (7 per cent) in the placebo group. In the placebo group, five patients were admitted to the ICU, and one unfortunately died by day 29. Serious adverse events were also less common in the sotrovimab group, and no safety issues were identified in the study.